Wegovy for MASH: what is approved, what the trial showed and who covers it
The short answer
Is Wegovy for MASH approved? Yes, with limits. Wegovy injection is approved, under accelerated approval, to treat noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults. At week 72 in the label trial, 63% on Wegovy versus 34% on placebo had resolution of steatohepatitis without worsening fibrosis. CMS, which runs Medicare, says this use is eligible for Part D coverage.
Key takeaways
- The MASH use is for adults without cirrhosis whose fibrosis is stage F2 or F3, under accelerated approval.
- It covers Wegovy injection only. Wegovy tablets, Ozempic and Rybelsus are not approved for MASH.
- On Medicare, use your Part D plan. A noncirrhotic MASH diagnosis with moderate to advanced scarring rules out the GLP-1 Bridge.
- Ask your prescriber to name MASH on the prescription, so your plan reviews it under the right rule.
Wegovy is the only one of the eight FDA-approved GLP-1 medicines with a liver use on its label. The approval is narrow, it applies to one form of the medicine, and it was granted under accelerated approval. This page explains each of those points and what the approval means for coverage. For the medicine in general, see the Wegovy guide.
What the label says
Our record of the Wegovy label lists this use: treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) in adults, under accelerated approval, for the injection.
MASH is metabolic dysfunction-associated steatohepatitis, a liver condition with fat and inflammation. Each part of the approved use narrows who it covers:
- Noncirrhotic. The use is for people whose liver disease hasn’t progressed to cirrhosis, which is severe, permanent liver scarring.
- Moderate to advanced fibrosis, F2 to F3. Fibrosis is liver scarring, and CMS describes this use as MASH “with moderate to advanced liver scarring (fibrosis).” F2 and F3 are the stages the label names. Earlier and later stages are outside the wording.
- Adults. The MASH use doesn’t include pediatric patients.
- Injection. Wegovy also comes as a daily tablet. The MASH use is listed for the weekly injection only.
- Accelerated approval. The label states that this use was approved under accelerated approval. Your prescriber or hepatologist (liver specialist) can explain what it means for you.
How fibrosis stage is established, and which tests your prescriber or insurer accepts, are clinical questions for your prescriber.
What the label trial showed at week 72
The label reports a trial in adults with MASH and stage 2 or 3 fibrosis, with liver tissue results at week 72. Its summary: “WEGOVY injection demonstrated improvement on these histopathology endpoints at Week 72 compared to placebo.”
The label table has two endpoints, or main results. Placebo here means an inactive treatment.
- Resolution of steatohepatitis without worsening of fibrosis: 63% of patients on Wegovy injection versus 34% on placebo.
- Improvement in fibrosis without worsening of steatohepatitis: 37% on Wegovy injection versus 22% on placebo.
The same section reports weight. Patients treated with Wegovy injection achieved an average of 10.5% weight loss from baseline (their weight at the start) at week 72, and patients on placebo an average of 2%.
Two cautions when you read these. They’re results on liver tissue (histopathology) measures at 72 weeks, and they’re group proportions. They don’t say what will happen in any one person’s liver. And not everyone responded. On the first endpoint, more than a third of the Wegovy group didn’t meet it.
What is not approved for MASH
- Wegovy tablets. Not listed for MASH.
- Ozempic and Rybelsus. Both contain semaglutide, as Wegovy does. Each brand has its own label and its own approved uses, and neither of these labels lists MASH.
- Zepbound, Mounjaro, Foundayo, Trulicity and Saxenda. No MASH use on their labels.
The Wegovy label also says using it with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. If you take one of those medicines for diabetes, your prescriber decides how a MASH diagnosis changes your treatment.
How Medicare treats a MASH prescription
Part D excludes drugs “when used for” weight loss, and that exclusion is why a Wegovy prescription for weight alone isn’t a covered Part D drug. A prescription for MASH is a different use. CMS, which runs Medicare, says an anti-obesity medication is coverable in Part D when used for another medically accepted indication, and it states plainly: “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage.”
Here’s what follows from that:
- Use your Part D plan. CMS says people with a GLP-1 prescription for an indication covered under Part D should obtain it through their Part D plan. Expect the plan to ask for prior authorization (its approval before it pays) with the diagnosis and fibrosis stage documented.
- The Bridge is closed to you. A diagnosis of noncirrhotic MASH with moderate to advanced liver scarring makes a person ineligible for the Medicare GLP-1 Bridge. The Bridge explainer covers the exclusion, including the looser “fatty liver disease” wording on Medicare.gov.
- A negotiated price applies from 2027. CMS and Novo Nordisk agreed a negotiated price of $274 for a 30-day supply of semaglutide for 2027. CMS lists $385.63 for a package of four Wegovy 2.4 mg pens. These are prices for the drug under Part D from January 1, 2027, not what you pay at the counter.
There’s more detail on the page about Medicare and Wegovy and in the Medicare guide.
Commercial insurance and paying cash
Commercial plans write their own criteria for the MASH use. Ask your plan what paperwork it requires. With commercial coverage, the Wegovy savings offer brings a fill to as little as $25, subject to its terms.
If you pay cash, the approved use doesn’t change the price. The Wegovy 2.4 mg pen is $349 a month through NovoCare. That strength is quoted as a price example, not as a statement of the dose used for MASH, which your prescriber sets from the label. The Wegovy cost page lists every price, and the cheapest path tool compares routes for your situation.
How the injection is taken
The label says Wegovy injection is given once weekly, on the same day each week, at any time of day, with or without meals. The dose schedule is on the Wegovy page, and the titration schedule tool lays out the label’s steps.
Questions for your prescriber
- Does my fibrosis stage fall within F2 to F3, and how was it measured?
- Will the prescription name MASH as the indication, so my plan reviews it under the right rule?
- What does accelerated approval mean for how long I might take this?
- How will you check whether the medicine is working for my liver?
Frequently asked questions
Is Wegovy FDA-approved for MASH?
Yes, with limits. Wegovy injection is approved, under accelerated approval, for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults. The approval covers the injection and not Wegovy tablets, and it doesn't cover MASH with cirrhosis.
What is MASH?
MASH stands for metabolic dysfunction-associated steatohepatitis, the term CMS and the Wegovy label use for this liver condition. Medicare.gov refers to it more simply as fatty liver disease. The Wegovy approval applies to a specific group: adults without cirrhosis whose liver fibrosis (scarring) is at stage F2 or F3.
Does Medicare cover Wegovy for MASH?
It can. CMS states that noncirrhotic MASH with moderate to advanced liver scarring is an indication eligible for Part D coverage, and that people with a GLP-1 prescription for a Part D covered indication should get it through their Part D plan. People with this diagnosis are not eligible for the Medicare GLP-1 Bridge.
Are Wegovy tablets approved for MASH?
No. The Wegovy label lists the MASH use for the injection only. Wegovy tablets are approved for weight reduction and for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and for nothing else.
Is Zepbound or Ozempic approved for MASH?
No. Among the eight FDA-approved GLP-1 medicines, only Wegovy injection lists a MASH use. Ozempic and Rybelsus also contain semaglutide, but their labels cover type 2 diabetes uses, and an approved use on one brand's label doesn't transfer to another brand.
Sources (12)
- 1.FDA label (DailyMed): Wegovy prescribing information, section 14.4, Table 21
“WEGOVY injection demonstrated improvement on these histopathology endpoints at Week 72 compared to placebo.”
- 2.FDA label (DailyMed): Wegovy prescribing information, section 14.4
“Patients treated with WEGOVY injection (mean baseline body weight 95.4 kg) achieved an average of 10.5% weight loss from baseline at Week 72, and patients treated with placebo (mean baseline weight 97.6 kg) achieved an average of 2% weight loss from baseline at Week 72”
- 3.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 4.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
- 5.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 6.CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
“Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
- 7.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 8.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
- 9.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4524-14. Description of package: 2.4mg/0.75mL Pen, 4 Pens (Wegovy). MFP per package: $385.63.”
- 10.
- 11.
- 12.
